Clinical trial
Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty
NCT00779103 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- April 30, 2012
- Enrollment
- 36 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
central precocious puberty